XML 14 R4.htm IDEA: XBRL DOCUMENT v3.23.3
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Operating Expenses:        
Research and development $ 3,380 $ 3,335 $ 9,721 $ 9,853
In-process research and development 0 30,393 0 30,393
General and administrative 2,584 3,992 9,962 10,815
Total operating expenses 5,964 37,720 19,683 51,061
Operating loss (5,964) (37,720) (19,683) (51,061)
Other income (expense):        
Investment income, net 714 337 2,053 496
Other expense, net (11) 0 (175) (149)
Total other income (expense) 703 337 1,878 347
Net loss before benefit from income taxes and noncontrolling interests (5,261) (37,383) (17,805) (50,714)
Benefit from income taxes 0 0 (2,330) (2,479)
Net loss (5,261) (37,383) (15,475) (48,235)
Less - net income attributable to noncontrolling interests 0 0 0 0
Net loss attributable to Lisata Therapeutics, Inc. common stockholders $ (5,261) $ (37,383) $ (15,475) $ (48,235)
Basic and diluted loss per share        
Lisata Therapeutics, Inc. common stockholders- basic (in usd per share) $ (0.65) $ (7.88) $ (1.92) $ (11.28)
Lisata Therapeutics, Inc. common stockholders - diluted (in usd per share) $ (0.65) $ (7.88) $ (1.92) $ (11.28)
Weighted average common shares outstanding        
Basic shares (in shares) 8,141 4,747 8,050 4,276
Diluted shares (in shares) 8,141 4,747 8,050 4,276